At Medrio, we believe that clinical trial technology shouldn’t be difficult to use. That’s why our full-service eClinical Data Management suite helps streamline your research and unify your solutions so you have more time to focus on your patients, rather than multiple vendors. Since 2005, our flexible technology has evolved alongside our customers to include an integrated suite of EDC, DDC, eConsent, RTSM, and ePRO/eCOA solutions that support your teams and sites, while reducing patient burden.
Let our solutions put you back in the driver’s seat with adaptive technology that easily powers mid-study changes and accelerates your trials, without compromising data quality. Or lean on our global team of experts who are available 24/7 to support you where you need it most. We’ve worked alongside Sponsors, CROs, and sites—spanning all therapeutic areas and trial phases—to secure over 375 approvals because we know it takes a village to achieve a healthier world.



  • Australia and New Zealand have not been impacted as much as North America and the EU with regards to COVID-19. For this reason, and their quick study-start timelines, this region could become very attractive to sponsors in the near future. In this podcast, Yvonne Lungershausen and Sandrien Louwaars discuss how Avance Clinical prepared for the pandemic, what tools they implemented that allowed trial continuation, and why clinical trials are currently thriving in the region.

  • Hope Biosciences focuses on stem-cell research to prevent disease and degeneration. In this podcast, the CEO of Hope Biosciences discusses the recent advances in stem-cell research, the potential stem-cells have for curing disease, and what she believes the future may hold. We’ll also discuss Hope Bio’s current COVID-19 trial and how stem-cell therapies are playing their part to combat this global pandemic.

  • Discover the ways in which a patient-centric approach can remove controllable barriers from the clinical trial process and strengthen patient engagement.

  • Due to COVID-19 the clinical trial industry has been adopting advanced clinical trial technology at warp speed, but what does this mean for the future? What is a sustainable approach to ensure the industry does not face the same challenges and delays should we be impacted by another pandemic or global crisis? In this podcast we sit down with Mary Mattes, Senior Vice President of Global Operations at Synteract to discuss decentralization of clinical trials and a hybrid model. 

  • Quartesian and Medrio have had a solid partnership since 2010 and have partnered together in over 250 studies. In this podcast, we’ll discuss the foundation of our successful partnership, eSource, and the innovative ways we are collaborating with Quartesian on a COVID-19 study currently underway.

  • Phastar and Medrio have been partnering together on trials for the past 3 years, culminating in a unique way to visualize clinical trial data. Through the use of Medrio’s API, Phastar has built a data visualization tool that reduces risk and allows for complete study oversight. In this podcast we’ll discuss the need for data visualization in clinical trials, how Phastar has continued their trials during a global pandemic, and what their thoughts are on the future of how we collect and view data.

  • Patients are no longer passive research subjects, but rather being integrated into the research process from the start. Advocating for a patient is advocating for a human being, not a test subject. As clinical research evolves more emphasis has been placed on patient experience, rather than just data points.

  • Reducing the number of vendors you interact with allows you to not only achieve higher quality data, you can also spend more time focusing on what matters- the patients. Our fully integrated RTSM and EDC allows you to spend more time focused on your data and less on outside programmers and vendors. In this episode we will explore the value of a combined solution and what you can expect in return.

  • Approximately 39.5% of all men and women will be diagnosed with cancer at some point during their lifetimes, and yet only 8% of oncology patients participate in clinical trials. Many industry leaders think that a greater focus on patient advocacy could be the missing link. In this podcast, Rose Gerber, Director of Patient Advocacy and Education at the Community Oncology Alliance – once a patient herself and now a dedicated advocate – will share her story and discuss how patient advocacy is helping to increase patient enrollment in clinical trials across every therapeutic area.




345 California Street, Suite 325

San Francisco, CA 94104


Phone: (415) 963-3700

Contact: Jillian Tygh


  • The clinical trials industry is buckling under the weight of continuously growing complexities. In this blog, read how developing an interconnected clinical trials ecosystem is essential to to minimizing the ripple effects of complexity impacting sites and patients.

  • In this paper, we’ll define what a hybrid trial is, how it utilizes decentralized technologies and the reason for mainstream adoption of hybrid clinical trials.

  • In a proof-of-concept for a decentralized hybrid study, Electronic Patient-Reported Outcomes (ePRO) technology was used to assess the results of varying digital therapies and the feasibility of conducting a largely virtual clinical study in a fibromyalgia population.

  • Explore how your eClinical can become a powerful tool for patient engagement that yields high-quality outcomes.

  • In this blog post, Melissa Newara explores several patient engagement strategies that sponsors, CROs, and clinicians can adopt to align their study protocol with relevant patient outcomes. 

  • Inadequate privacy preparation can result in lengthy reviews and delayed approvals by Institutional Review Boards (IRBs), jeopardize trust in the patient-clinical relationship, and result in costly delays to your trial timelines. This article will aim to address common issues and gray areas related to collecting and protecting PHI, as well as proven ways to enhance compliance with HIPAA regulations.

  • The fragile patient populations in orphan drug studies require an innate understanding of their clinical disease and how they and their caregivers experience it in their daily lives. Researchers must design their trials in a way that considers their unique populations.

  • Innovative clinical trial technologies are helping researchers find the balance between keeping patients enrolled and active and monitoring the increased protocol complexity and rising costs. Read below to see how novel technologies are reducing complexities in trials and supporting stronger, more intentional engagement that results in stronger patient outcomes.

  • Electronic patient-reported outcome (ePRO) solutions are helping bridge the gap between patient-centric workflows that engage patients while generating higher quality, more reliable data that successful studies need. This blog explores the role ePRO plays in patient engagement and how to harness it moving forward.

  • Although the pandemic isn’t behind us, trends are suggesting that decentralized trials are here to stay. But what does the future of decentralized clinical trials look like? This article explores emerging trends resulting from decentralized trials during COVID-19 and what they suggest about the future of DCT.


  • Randomization & Trial Supply Management (RTSM) aims to alleviate these pain points by solving high-risk and high-cost trial needs through an intelligent approach to operational management. Due to the inherently changing nature of randomized trials, both adaptive designs and master protocols require a highly sophisticated RTSM solution to swiftly and efficiently introduce mid-study protocol adjustments. In this whitepaper, read about the benefits of incorporating a robust RTSM.

  • See how sponsors and CROs must put themselves into the mindsets of their patients and find ways to incorporate their needs into the entire clinical trial lifecycle.

  • What steps can sponsors and CROs take to position their early-stage studies for success and expedite their final market approval? In this article, we’ll explore three obstacles that researchers face early in phase I studies, as well as some insight into how the right eClinical suite can overcome those challenges.

  • Planned and unplanned mid-study changes add an average of 30 days to clinical trial timelines, according to a new study by the Tufts Center for the Study of Drug Development (CSDD). This blog highlights more findings from this survey and expert insights on how to overcome the challenges of mid-study changes.